Langtidsstudier viser, at Levemir forbedrer fasteplasmaglukose hos patienter med type 1 diabetes inklusive børn og unge fra 6 år til 17 år i basal/ bolusbehandling i forhold til NPH- insulin.
In long-term treatment trials in patients with type 1 diabetes, fasting plasma glucose was improved with Levemir compared with NPH insulin when given as basal/ bolus therapy including in children and adolescents aged 6 to 17 years.